Latest News-Porda Havas International Financial Communications Group Mediaroom_Page

Baguio wins EPD service contract worth HK$37 million to provide food waste collection services in New Territories West

HONG KONG, Jan. 16, 2023 /PRNewswire/ -- Baguio Green Group Limited ("Baguio" or the "Company", Sto...

2023-01-16 20:41 2443

PAAMC HK Announces Winning in ESG Leading Enterprise Awards 2022

HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Ping An of China Asset Management ( Hong Kong) Company Limi...

2022-12-14 16:30 1649

Baguio wins FEHD contracts worth HK$482 million driving total Contracts on Hand to a historical high level

HONG KONG, Sept. 30, 2022 /PRNewswire/ -- Baguio Green Group Limited ("Baguio" or the "Company", St...

2022-09-30 17:51 3708

PAAMC HK Honored to be Included in 4 Prestigious IAMAC Recommendations

HONG KONG and SHANGHAI, Sept. 27, 2022 /PRNewswire/ -- Ping An of China Asset Management (Hong Kong...

2022-09-27 16:30 2239

Baguio's Net Profit Increased by 45%

Contracts On Hand Recorded a Historical High with a Substantial Increase of around 60% to HK$3.4 bi...

2022-08-30 23:01 3612

Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization

BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (...

2022-08-26 22:09 10749

SZSE Issued Evaluation Method of ESG and ESG Indices to Improve SZSE Characteristic Index System and Provide Services to Low-Carbon and Sustainable Development

SHENZHEN, China, Aug. 11, 2022 /PRNewswire/ -- On July 25, Shenzhen Securities Information Co., Ltd...

2022-08-11 16:33 1979

Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration

BEIJING, June 23, 2022 /PRNewswire/ -- Ocumension Therapeutics （1477.HK）announced that the New Drug...

2022-06-23 12:19 2157

An In-Depth Look at the Annual Performance of SZSE Core Indices Constituent Companies

SHENZHEN, China, June 6, 2022 /PRNewswire/ -- All constituents of the key indices of the Shenzhen S...

2022-06-06 19:38 2507

SZSE Makes New Progress in Implementing High-standard Two-way Opening-up ChiNext Index Becomes an Important Target for Foreign Investors to Invest in China A-shares

SHENZHEN, China, June 2, 2022 /PRNewswire/ -- The SZSE ChiNext Daily (2x) Leveraged Product recentl...

2022-06-02 17:30 1892

Ping An Overseas Holdings Announces Successfully Raising USD 300 Million for China New Economy Fund

HONG KONG, May 18, 2022 /PRNewswire/ -- China Ping An Insurance Overseas (Holdings) Limited, the ...

2022-05-18 16:15 1741

Peijia Medical Announces 2021 Annual Results

Dual Engines Promote Commercialization Total Revenue Increased by 253.2% HONG KONG, April 2, 2022 ...

2022-04-02 00:06 9844

Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a lea...

2022-02-23 17:53 2348

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code...

2022-02-16 17:04 2699

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code:...

2022-02-09 17:12 1498

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code:...

2022-02-09 17:10 1749

Latest News

Baguio wins EPD service contract worth HK$37 million to provide food waste collection services in New Territories West

PAAMC HK Announces Winning in ESG Leading Enterprise Awards 2022

Baguio wins FEHD contracts worth HK$482 million driving total Contracts on Hand to a historical high level

PAAMC HK Honored to be Included in 4 Prestigious IAMAC Recommendations

Baguio's Net Profit Increased by 45%

Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization

SZSE Issued Evaluation Method of ESG and ESG Indices to Improve SZSE Characteristic Index System and Provide Services to Low-Carbon and Sustainable Development

Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration

An In-Depth Look at the Annual Performance of SZSE Core Indices Constituent Companies

SZSE Makes New Progress in Implementing High-standard Two-way Opening-up ChiNext Index Becomes an Important Target for Foreign Investors to Invest in China A-shares

Ping An Overseas Holdings Announces Successfully Raising USD 300 Million for China New Economy Fund

Peijia Medical Announces 2021 Annual Results

Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.

Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm

PAAMC HK Announces Winning in ESG Leading Enterprise Awards 2021

Ping An Overseas Holdings Raised Funds of USD 750 Million for Overseas Private Equity Investing